Realm Ther­a­peu­tics shares crater — again — on a failed PhII atopic der­mati­tis study

A lit­tle over a year af­ter Realm Ther­a­peu­tics put to­geth­er a transat­lantic syn­di­cate to back a $26 mil­lion ven­ture round, the biotech has been watch­ing its stock $RLM crater af­ter a Phase II fail­ure for their lead ther­a­py. And this is their sec­ond Phase II flop in 5 months.

Re­searchers for the Malvern, PA-based biotech had hoped to get some sol­id sup­port­ing da­ta from their mid-stage study of PR022 in atopic der­mati­tis — plan­ning to re­cruit 120 tri­al sub­jects to test the top­i­cal gel — but they couldn’t see any im­prove­ment over the con­trol arm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.